A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

  • STATUS
    Recruiting
  • End date
    Jun 6, 2024
  • participants needed
    30
  • sponsor
    The Affiliated Hospital of Xuzhou Medical University
Updated on 6 January 2022

Summary

A Phase Ⅱ, open-label, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer.

Description

A Phase 2, open-label, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer).

Details
Condition Biliary Tract Cancer
Treatment Surufatinib Toripalimab
Clinical Study IdentifierNCT05056116
SponsorThe Affiliated Hospital of Xuzhou Medical University
Last Modified on6 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male and Female aged between 18 and 75 years are eligible; Provision of written Informed Consent Form (ICF) prior to any study specific procedures
Advanced (unresectable) or metastatic biliary carcinomas that have been histologically or cytologically confirmed include intrahepatic or extrahepatic carcinoma of the bile duct, carcinoma of the gallbladder, and carcinoma of the ampullary of fatt, and have been histologically confirmed as adenocarcinoma
Patients who have previously received disease progression or toxic side effects after first-line systemic chemotherapy are not tolerated;The standard first-line chemotherapy regimen was defined as a two-drug combination regimen of gemcitabine plus cisplatin, gemcitabine plus gio, or capecitabine plus oxaliplatin.Failure of first-line standard chemotherapy was defined as progression of disease during treatment or within 6 months after the last treatment;Or the toxic side effects of the treatment process are intolerable
Presence of at least one measurable target lesion for further evaluation according to RECIST criteria
Patients who had previously received A VEGF or VEGFR-targeted drug required progression 4 months after the last dose
No systemic antitumor therapy in 4 weeks
The patient has no evidence of biliary obstruction unless the obstruction is controlled by local treatment or the patient is decompressed by endoscopic or percutaneous stenting, and bilirubin is subsequently reduced to below the upper limit of 1.5x normal (ULN)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1;Predicted survival ≥3 months;
Screening laboratory values must meet the following criteria (within past 14 days)
neutrophils ≥1.5×109/L ;
platelets ≥9g/dL;
hemoglobin ≥ 9.0 g/dL;
albumin≥3g/dL;
total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1.5╳ULN
Voluntary enrollment, good compliance, can cooperate with the experiment observation
Males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 6 months after the last dose of study drug
and signed a written informed consent

Exclusion Criteria

Prior treatment with Surufatinib,or other antiangiogenic drugs were used within 6 months
Prior antitumor therapy with chemotherapy, radical radiation therapy ,biological immunotherapy,targeted therapy within 4 weeks
Prior participation in other clinical trials not approved or listed in China within past 4 weeks;
Prior major surgery within past 4 weeks (diagnostic surgery excluded)
International standardized ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5×ULN
Clinically significant severe electrolyte abnormality judged by investigator
Hypertension that is not controlled by the drug, and is defined as: SBP≥140 mmHg and/or DBP≥90 mmHg
The patient currently has disease or condition that affects the absorption of the drug, or the patient cannot be administered orally
Currently suffering from poorly controlled diabetes (after regular treatment, fasting plasma glucose concentration ≥10mmol/L)
Digestive tract disease such as gastric and duodenal active ulcer, ulcerative colitis or unresected tumor, or other conditions determined by the investigator that may cause gastrointestinal bleeding and perforation
Evidence of bleeding tendency or history within 3 months, or thromboembolic event (including a stroke event and/or a transient ischemic attack) occurred within 12 month
Cardiovascular disease of significant clinical significance (myocardial infarction, unstable arrhythmia or unstable angina ,Coronary Artery Bypass Grafting within past 6 months,);
Had other malignant tumors in the past 5 years (except for basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ that have been effectively controlled)
Active or uncontrolled severe infection (≥CTCAE2 infection)
Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA (>2000IU/ml)
Evidence with active CNS disease or previous brain metastases
The toxicity associated with previous anti-tumor treatment has not recovered to ≤CTCAE1, except for peripheral neurotoxicity and alopecia ≤CTCAE2 caused by oxaliplatin
Transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony stimulating factor (G-CSF), had been received within 14 days before enrollment
Pregnant or nursing;
Tumor involving skin and/or pharyngeal mucosa with ulceration
Patients with a history of psychotropic drug abuse and unable to quit or with mental disorders
Any other disease, with clinical significance of metabolic abnormalities, abnormal physical examination or laboratory abnormalities, according to researchers, there is reason to doubt is not suitable for the use of study drugs in patients with a disease or condition (such as have a seizure and require treatment), or will affect the interpretation of results, or make the patients at high risk
Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events
Routine urine indicated that urine protein ≥2+, and the 24-hour urine protein volume >1.0g
Prior receipt of any anti-PD-1 /PD-L1/PD-L2 antibody or anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) antibody or any other antibody acting on T cell co-stimulation or checkpoint pathway (e.g. OX40, CD137, etc.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note